These results suggest that FPB can improve hepatitis by regulating TLR-4/MyD88/NF-κB signaling pathway caused by hyperglycemia in HFD-induced NAFLD mice. Here, MYD88 is linked to metabolic dysfunction-associated steatotic liver disease.